{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-039348","form_type":"8-K","ticker":"COYA","cik":"0001835022","company_name":"Coya Therapeutics, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.593818+00:00","generated_at":"2026-06-12T02:46:41.935262+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Coya Therapeutics Q2 2023 net loss $3.1M; highlights positive AD and ALS clinical data","bullets":["Net loss of $3.1M ($0.31 per share) for Q2 2023 vs $3.4M loss in Q2 2022.","Cash and equivalents $13.1M as of June 30, 2023, up from $5.9M at Dec 31, 2022.","Positive PoC data for ld IL-2 in Alzheimer's: statistically significant MMSE improvement and reduced neuroinflammation.","ALS study of COYA 302 halted disease progression at 24 weeks; pre-IND meeting with FDA planned for H2 2023.","Appointed Dr. Fred Grossman as President/CMO and Arun Swaminathan as CBO."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-039348","json":"https://secwatch.observer/filing/0000950170-23-039348.json","markdown":"https://secwatch.observer/filing/0000950170-23-039348.md","text":"https://secwatch.observer/filing/0000950170-23-039348.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835022/000095017023039348/0000950170-23-039348-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835022/000095017023039348/coya-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:46:41.935262+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f6604242972c0d96d468acfddf08535a929d13a4","claim":"Coya Therapeutics, Inc. reported financial results for second quarter ended June 30, 2023.","evidence_excerpt":"On August 8, 2023, Coya Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the fiscal quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835022/000095017023039348/0000950170-23-039348-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}